TB-500 vs Sermorelin: What's the Difference

TB-500 and sermorelin differ in family and in what each one is studied for: TB-500 is a synthetic fragment of Thymosin Beta-4, investigated in tissue-repair models, while sermorelin is an analog of growth hormone-releasing hormone (GHRH), investigated in the growth hormone axis. They are not interchangeable and they are not comparable on "potency" — they answer different research questions entirely.

The confusion shows up often because both names circulate together in forums and peptide lists marketed around "recovery," but the literature places them on separate shelves. It is worth understanding why before choosing one for a lab protocol.

What TB-500 is, according to the literature

TB-500 is the synthetic, smaller-sized version of Thymosin Beta-4 (TB4), a protein that binds actin — the protein that forms the cellular cytoskeleton. That actin-binding property is what in vitro literature uses to explain why TB4 and its fragments are studied in models of cell migration, angiogenesis, and tissue remodeling.

Published studies on TB4/TB-500 are, overwhelmingly, done in cell culture or in animal models (primarily rodents). They aim to understand the protein's role in wound-healing and tissue-remodeling processes, not in people. It belongs to the family of cytoskeletal regulators, and that is where the resemblance to sermorelin ends: neither compound acts on the same receptor or operates in the same biological pathway as the other.

What sermorelin is, according to the literature

Sermorelin is a 29-amino-acid peptide corresponding to the active fragment of human GHRH — the hormone that, in the hypothalamic-pituitary axis, stimulates the release of growth hormone (GH) from the pituitary. Research on sermorelin concentrates precisely on that axis: the GHRH receptor in the pituitary, pulsatile GH secretion, and from there, the GH/IGF-1 axis.

By design, sermorelin shares a family with other GHRH analogs that make up the catalog entry for sermorelin and with compounds like CJC-1295 without DAC, which pursues the same pathway with a different half-life in the models where it is studied. The difference between sermorelin and CJC-1295 without DAC is one of kinetics within the same family; the difference between sermorelin and TB-500 is a difference of family entirely.

The real difference: mechanism, not "strength"

This is the point most comparisons circulating online get wrong: there is no common scale on which TB-500 is "stronger" or "weaker" than sermorelin. They are distinct axes of study:

• TB-500 is investigated in the actin and tissue-repair pathway (cell migration, angiogenesis, tissue remodeling in animal models).
• Sermorelin is investigated in the GH/IGF-1 axis pathway (GHRH receptor, pulsatile GH secretion, pituitary response).

Asking "which one is better" is like asking whether a reagent for studying coagulation is better than one for studying glucose metabolism: the answer depends on which research question the protocol in front of you is asking, not on a hierarchy between the two compounds.

This also explains why, in research practice, each one shows up paired with different partners. TB-500 is typically studied alongside BPC-157 — another peptide from the tissue-repair family, and in fact PeptoClinic has published a laboratory report on a combined BPC-157 and TB-500 vial — while sermorelin is typically studied alongside other GH-axis analogs such as tesamorelin. Each family has its own set of reasonable comparisons, and crossing families does not produce useful information.

What the laboratory documentation shows

PeptoClinic publishes batch-analysis reports from Janoshik Analytical, the same independent laboratory that issued the four reports underlying the catalog's documentation, all dated April 13, 2026. The most conservative figure among those reports — the one worth citing instead of the best case — is a purity of 99.669% found in one of the analyzed batches. That is the documented floor, not the average and not the best result.

Not every published report lists an explicit purity percentage: the report on the combined BPC-157 and TB-500 vial (10 mg total, 5 mg of each compound) and the one on GHK-Cu are verifiable, but the report itself does not state that specific figure. The correct way to read this — and, in general, the correct way to read any certificate of analysis before trusting it — is explained on the quality and documentation page.

What is consistent across every compound in the catalog is the standard PeptoClinic states for research material: purity of 99% or higher by HPLC, USP-grade diluents, and batch documentation available for review before confirming a quote.

Research material, not for human or veterinary use

Everything PeptoClinic supplies — including TB-500 and sermorelin — is provided strictly as research material (Research Use Only). Neither compound is approved for human or veterinary use, neither is a drug nor a supplement, and no regulatory authority has evaluated these statements. PeptoClinic is not a pharmacy, clinic, or telehealth provider; it does not issue dosing protocols or administration guidance, and it does not participate in any use outside the laboratory setting.

If the goal is to design a study protocol in Argentina with either compound — or with other peptides from the GH axis or the tissue-repair family — the starting point is the shipping and documentation page for Argentina and the full catalog, where the specification for each available batch is listed.